Sugi Predict

Sugi Predict / Compounds / SCHEMBL178372

SCHEMBL178372

SCHEMBL178372

CCC1CCC(CN)CC1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NCF1 P14598 1/20 0.48
▸ PLG P00747 1/20 0.44
▸ PLAT P00750 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ NOS3 P29474 3/20 0.34
▸ NOS1 P29475 3/20 0.34
▸ NOS2 P35228 3/20 0.34
▸ EPHX2 P34913 1/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ CYP2D6 P10635 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12441541 1.00 NCF1 (0.48) NCF1PLGPLATLMNANOS3
SCHEMBL12820123 1.00 NCF1 (0.48) NCF1PLGPLATLMNANOS3
SCHEMBL23139644 0.92 NCF1 (0.42) NCF1PLGPLATLMNANOS3
Ethylamine SCHEMBL9829381 0.87 — —
Ethylamine SCHEMBL7195531 0.87 — —
SCHEMBL23022334 0.86 CYP2D6 (0.45) NCF1PLGPLATLMNANOS3
SCHEMBL19769337 0.85 SAT1 (0.42) NCF1PLGPLATLMNAEPHX2
Propane SCHEMBL29072154 0.84 — —
Methylamine SCHEMBL7191983 0.83 — —
SCHEMBL6802 0.83 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
WO-2023177356-A2 COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION ENGINE BIOSCIENCES PTE. LTD. (SG) 2023-09-21 — — WO disclosed
WO-2023138204-A1 PREPARATION METHOD FOR SSZ-16 COPPER-CONTAINING CATALYST 天津派森新材料技术有限责任公司 2023-07-27 — — WO disclosed
WO-2023029928-A1 AMINO LIPID AND APPLICATION THEREOF 深圳虹信生物科技有限公司 2023-03-09 — — WO disclosed
US-20230065740-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. 2023-03-02 — — US disclosed
US-20220396587-A1 MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2022-12-15 — — US disclosed
EP-3766878-B1 NRF2 REGULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2022-03-16 — — EP disclosed
US-20220056037-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. 2022-02-24 — — US disclosed
EP-3541793-B1 PROCESS FOR THE MANUFACTURING OF TRIARYL-ALKYL BORATES COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2021-03-31 — — EP disclosed
EP-1259262-B1 HYDROLYTICALLY DEGRADABLE CARBAMATE DERIVATIVES OF POLY(ETHYLENE GLYCOL) NEKTAR THERAPEUTICS AL CORP (US) 2007-03-14 — — EP disclosed
US-20050171128-A1 Pyrrolo[2,3-d]pyrimidine compounds PFIZER INC 2005-08-04 — — US disclosed
US-6890929-B2 Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease PFIZER, INC. (US) 2005-05-10 — — US disclosed
EP-1087970-B1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS PFIZER PROD INC (US) 2004-04-28 — — EP disclosed
US-20040014763-A1 beta-sheet mimetics and composition and methods relating thereto MYRIAD PHARMACEUTICALS, INC. (US) 2004-01-22 — — US disclosed
US-20030212273-A1 Pyrrolo [2,3-D] pyrimidine compounds PFIZER INC. 2003-11-13 — — US disclosed
US-6610847-B2 Tyrosine kinase inhibitors; immunosuppressants PFIZER INC. 2003-08-26 — — US disclosed
US-20020019526-A1 Pyrrolo[2,3-d]pyrimidine compounds PFIZER INC. 2002-02-14 — — US disclosed
EP-1087970-A1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS Pfizer Products Inc. (US) 2001-04-04 — — EP disclosed
WO-1999065908-A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS PFIZER PRODUCTS INC. (US) 1999-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014763-A1 beta-sheet mimetics and composition and methods relating thereto TPSAB1, TPSB2, TPSD1 NCF1 3823/4885PLG 263/4885PLAT 301/4885
US-20220396587-A1 MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS MCL1, BCL2A1, BCL2L1 NCF1 1820/4885PLG 3723/4885PLAT 4076/4885
US-20220056037-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK2, CDK1, CCNK NCF1 1308/4885PLG 2938/4885PLAT 2329/4885
US-20020019526-A1 Pyrrolo[2,3-d]pyrimidine compounds JAK1, JAK3, JAK2 NCF1 1894/4885PLG 2668/4885PLAT 1436/4885
US-20230065740-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK2, CDK1, CCNK NCF1 1308/4885PLG 2938/4885PLAT 2329/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 NCF1 2891/4885PLG 1441/4885PLAT 1236/4885
US-20050171128-A1 Pyrrolo[2,3-d]pyrimidine compounds JAK3, JAK1, JAK2 NCF1 2256/4885PLG 2534/4885PLAT 1286/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 NCF1 2891/4885PLG 1441/4885PLAT 1236/4885
US-20030212273-A1 Pyrrolo [2,3-D] pyrimidine compounds JAK1, JAK3, JAK2 NCF1 1894/4885PLG 2668/4885PLAT 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.